AtmosR is a biotech startup that focuses on developing pioneering treatments for rare and severe disorders of the central nervous system. Their flagship drug, ATS-003, aims to restore autonomous breathing in CCHS patients, thus eliminating a critical risk and enabling greater independence. Founded in 2019, the company is based in Aix en Provence and Paris. The most recent investment, a non-equity assistance investment, was received on 03 January 2022 from Incubateur Impulse.
AtmosR
Pioneering treatments to restore autonomous breathing and safety for those with rare central nervous system disorders.
Founded 2019
2-10 employees
Non Equity Assistance
Biotechnology, Health Care
General Information
Company Name
AtmosR
Founded Year
2019
Employees
2-10
Industries
Biotechnology, Health Care
Funding Stage
Non Equity Assistance
BounceWatch is an independent company data service, not affiliated with AtmosR. To contact AtmosR, visit atmosr.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
About AtmosR
Taxonomy: biotech company, central nervous system disorders, ATS-003, rare disorders, autonomous breathing, CCHS patients, innovative treatments, Aix en Provence, Paris, drug development, rare disease, neurological disorders
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Undisclosed | 1 |
|
03 Jan 2022 |
AtmosR Alternatives & Competitors
View All Alternatives
AtmosR vs
Pioneering advancements in central nervous system treatments with innovative solutions for crossing...
Series A
Biotechnology, Health Care
AtmosR vs
Cerebral Therapeutics, Inc.
United States
A clinical stage pharmaceutical company developing innovative treatments for neurological disease.
Series C
22 employees
Biotechnology, Health Care
AtmosR vs
Umecrine Cognition AB
Sweden
A novel and safe approach for treating cognitive disorders
Convertible Note
11 employees
Biotechnology, Health Care
FAQ About AtmosR
Pioneering treatments to restore autonomous breathing and safety for those with rare central nervous system disorders.
AtmosR was founded in 2019.
AtmosR operates in Biotechnology and Health Care. Its work centres on biotech company, central nervous system disorders, ATS-003 and rare disorders.
AtmosR has approximately 2-10 employees.
AtmosR has completed 1 funding round. The latest funding stage is Non Equity Assistance.
Top alternatives and competitors to AtmosR include Travecta Therapeutics, Cerebral Therapeutics, Inc., Umecrine Cognition AB, Emalex Biosciences, CNS Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AtmosR and Travecta Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for AtmosR, https://bouncewatch.com/company/atmosr, updated 2 January 2025. When citing, please name BounceWatch and link this page.
